Inhibitory effect of caffeic acid esters on modulation of azoxymethane-induced early events and aberrant crypt foci formation in rat colon (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Inhibitory effect of caffeic acid esters on modulation of azoxymethane-induced early events and aberrant crypt foci formation in rat colon (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 34:A986 1993. Unique Identifier : AIDSLINE ICDB/93691957
Rao CV; Desai D; Simi B; Kulkarni N; Amin S; Reddy BS; American Health Foundation, Valhalla, NY 10595

Abstract: Caffeic acid (CA) esters present in the propolis of honey bee hives are potent inhibitors of human colon tumor cell growth. We investigated the inhibitory effect CA esters, namely methyl caffeate (MC), phenylethyl caffeate (PEC), phenylethyl-3-methyl caffeate (PE-3-MC) and phenylethyldimethyl caffeate (PEDMC) on azoxymethane (AOM)-induced ornithine decarboxylase (ODC), tyrosine protein kinase (TPK), arachidonic acid metabolism and aberrant crypt foci (ACF) that are relevant to colon carcinogenesis. At 5 wk of age, groups of male F344 rats were fed diets containing 600 ppm of MC and PEC (biochemical study) or 500 ppm of PEC, PE-3-MC and PEDMC (ACF study). Two weeks later, all animals (except the vehicle-treated) were given sc injection of AOM, once weekly for 2 wk. The animals intended for biochemical and ACF study were sacrificed 5 days and 9 wk later, respectively. PEC significantly suppressed the colonic ODC (p less than 0.01), TPK (p less than 0.001) and lipoxygenase pathway of arachidonic acid metabolism (p less than 0.001), whereas MC inhibited the TPK activity (p less than 0.01) only. AOM-induced colonic ACF was significantly inhibited in animals fed PEC (56%), PE-3-MC (83%) and PEDMC (81%) as compared with those fed the control diet. These results suggest that PE-3-MC and PEDMC possess chemopreventive properties for colon cancer.

Keywords: Animal Arachidonic Acid/METABOLISM Azoxymethane/*ANTAGONISTS & INHIB/PHARMACOLOGY Caffeic Acids/PHARMACOLOGY/*THERAPEUTIC USE Colonic Neoplasms/*DRUG THERAPY/METABOLISM/PATHOLOGY Ornithine Decarboxylase/METABOLISM Protein-Tyrosine Kinase/METABOLISM Rats Rats, Inbred F344 ABSTRACT
931030
M93A0775

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .